Sarepta Therapeutics Inc (SRPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.72B
Last updated: Nov 17, 2026 at 4:38 PM ET
Sarepta Therapeutics Inc (SRPT) Stock Chart
Sarepta Therapeutics (SRPT) has a latest price of $14.77 on Nov 17, 2026, 40.2% below its 52-week high of $24.68. Its price fell 21.5% over the past 12 months. The month-end price fell 52.5% over the 10 years through Oct 2026, a compound annual decline of 7.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $170.49 in Dec 2020 and its lowest $14.86 in Jul 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart SRPT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for SRPT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 25.1%, and over 6 months it fell 11.2%. The month-end price fell 72.3% over the 3 years through Oct 2026, a compound annual decline of 34.8%.
| Period | Change |
|---|---|
| 1 month | -16.7% |
| 3 months | -25.1% |
| 6 months | -11.2% |
| 12 months | -21.5% |
| 12 months, with dividends | -21.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -72.3% | -34.8% |
| 5 years | -76.5% | -25.1% |
| 10 years | -52.5% | -7.2% |
Price by Year
Its best calendar year was 2017, when the price rose 102.8%, and its weakest was 2025, when it fell 82.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $18.62 | -13.5% |
| 2025 | $21.52 | -82.3% |
| 2024 | $121.59 | +26.1% |
| 2023 | $96.43 | -25.6% |
| 2022 | $129.58 | +43.9% |
| 2021 | $90.05 | -47.2% |
| 2020 | $170.49 | +32.1% |
| 2019 | $129.04 | +18.2% |
| 2018 | $109.13 | +96.1% |
| 2017 | $55.64 | +102.8% |
Trading Range
The price is 19.4% below its 50-day average of $18.32 and 20.0% below its 200-day average of $18.46.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $14.77 | |
| 52-week high | $24.68 | -40.2% |
| 52-week low | $14.68 | +0.6% |
| 50-day average | $18.32 | -19.4% |
| 200-day average | $18.46 | -20.0% |
Price Risk
Over 3 years, its largest fall from a peak was 92.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.74 |
| Largest fall, 1 year | -38.0% |
| Largest fall, 3 years | -92.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About SRPT
What is SRPT's 1-year price change?
Sarepta Therapeutics's price fell 21.5% over the past 12 months. With dividends included, the 12-month total return was -21.5%.
What is SRPT's 5-year price change?
Sarepta Therapeutics's month-end price fell 76.5% over the 5 years through Oct 2026, a compound annual decline of 25.1%. These figures leave out dividends.
What is SRPT's 52-week high and low?
Sarepta Therapeutics's 52-week high is $24.68 and its 52-week low is $14.68. Its latest price of $14.77 on Nov 17, 2026 is 40.2% below the high.
What is SRPT's beta?
Sarepta Therapeutics's 1-year beta against the S&P 500 is 1.74, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 38.0%.
Is the SRPT chart free?
Yes. Advanced Charting for SRPT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
SRPT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors